The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
Open accessAbstract
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between drug responsiveness, tolerance and resistance, especially in the absence of preexisting subclones, remains unclear. In epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma cells, we demonstrate that residual disease and acquired resistance in response to EGFR inhibitors requires Aurora kinase A (AURKA) activity. Nongenetic resistance through the activation of AURKA by its coactivator TPX2 emerges in response to chronic EGFR inhibition where it mitigates drug-induced apoptosis. Aurora kinase inhibitors suppress this adaptive survival program, increasing the magnitude and duration of EGFR inhibitor response in preclinical models. Treatment-induced activation of AURKA is associated with resistance to EGFR inhibitors in vitro, in vivo and in most individuals with EGFR-mutant lung adenocarcinoma. These findings delineate a molecular path whereby drug resistance emerges from drug-tolerant cells and unveils a synthetic lethal strategy for enhancing responses to EGFR inhibitors by suppressing AURKA-driven residual disease and acquired resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An independent study by Shah et al. found that activation of aurora kinase A (AURKA) in TKI-treated drug-tolerant EGFR-mutant cells suppressed drug-induced apoptosis by increasing BIM phosphorylation and subsequent degradation [94].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Varghese, F., Bukhari, A. B., Malhotra, R., & De, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096801 · Cited by 1,318
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665
Cited by
Sorted by citations
Items 201–291 of 291
Sun, Y., Zhang, Z., Zhang, K., Liu, Y., Shen, P., Cai, M., Jia, C., Wang, W., Gu, Z., Ma, P., et al. (2021) · PubMed Central · Cited by 6
Mahfoudhi, E., Ricordel, C., Lécuyer, G., Mouric, C., Léna, H., & Pedeux, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.853501 · Cited by 7
Celeste, F., & Powers, S. (2024) · Cancers · doi:10.3390/cancers16051001 · Cited by 6
Yeo, H., Lee, H., Park, S., & Kang, H. N. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123097 · Cited by 6
López-González, J. S., Perez-Medina, M., Galicia-Velasco, M., & Aguilar‐Cázares, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771061 · Cited by 5
Quantitative Framework for Bench-to-Bedside Cancer Research
Zaman, A., & Bivona, T. G. (2022) · Cancers · doi:10.3390/cancers14215254 · Cited by 6
Self-citationLi, L., Lu, M., Wang, H., Ma, X., Du, W., Zhao, Y., Zeng, S., Peng, Y., & Zhang, G. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108393 · Cited by 6
Brunet, L. J., Alexandre, D., Lee, J., Blanquer-Rosselló, M. D. M., Bracquemond, D., Guernet, A. A., Chhouri, H., Goupil, M., Kherrouche, Z., Arabo, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61788-w · Cited by 5
Yang, P.-J., Hsieh, M., Lee, C., Yen, C., Wang, H., Chiang, W.-L., Liu, T.-C., Tsao, T. C. Y., Lee, C., & Yang, S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17197350 · Cited by 5
Hao, J., Peng, Q., Wang, K., Yu, G., Pan, Y., Du, X., Hu, N., Zhang, X., Qin, Y., & Li, H. (2021) · BioMed Research International · doi:10.1155/2021/6613439 · Cited by 5
A landscape of synergistic drug combinations in non-small-cell lung cancerPreprint
Nair, N. U., Greninger, P., Friedman, A. A., Amzallag, A., Cortez, E., Sahu, A. D., Lee, J. S., Dastur, A., Egan, R. K., Murchie, E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.03.447011 · Cited by 5
Gini, B., Gui, P., Wu, W., Kerr, D. L., Tan, L., Barbosa, D., Olivas, V. R., Allegakoen, P., Gomez, C., Halliday, P. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.12.584638 · Cited by 5
Self-citationTolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies
Sanchez-Cespedes, M., Lockwood, W. W., Suda, K., Gardner, E. E., Mitsudomi, T., Politi, K., Rolfo, C., Sen, T., Sos, M. L., Tammela, T., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100944 · Cited by 5
Non–Small Cell Lung Cancer to Small Cell Lung Cancer Transformation: A Clinical Challenge
Papavassiliou, K. A., Sofianidi, A. A., Gogou, V. A., Marinos, G., & Papavassiliou, A. G. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202410-1959pp · Cited by 4
Resistance to Allosteric Inhibitors
Outhwaite, I. R., Kwan, I., Leyte-Vidal, A., Shah, N. P., Bahar, İ., & Seeliger, M. A. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169133 · Cited by 5
Lin, X., Pan, F., Abudoureyimu, M., Wang, T., Hao, L., & Wang, R. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149247 · Cited by 4
Dong, S., Liang, J., Zhai, W., & Yu, Z. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1126 · Cited by 4
Aurora Kinase A: Bridging Breast Cancer Therapy and Disability-Inclusive Care
Sen, A., Singh, P., Jangra, S., & Srivastava, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-40858-8_469-1 · Cited by 4
Miyashita, Y., Tajima, K., Izumi, K., Matsumoto, N., Hayakawa, D., Nakamura, I. T., Katayama, I., Wibowo, A., Matsuda, H., Winardi, W., et al. (2025) · Cancer Science · doi:10.1111/cas.70032 · Cited by 3
Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance
Yeo, H., Kim, S.-Y., & Park, S. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01590-w · Cited by 4
Aurora B facilitates cholangiocarcinoma progression by stabilizing c‐Myc
Liu, K., Zhou, X., Huang, F., Liu, L., Xu, Z., Gao, C., Zhang, K., Hong, J., Yao, N., & Cheng, G. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12370 · Cited by 3
Hsa-miR-21 promoted the progression of lung adenocarcinoma by regulating LRIG1 expression
Liu, L., Liu, X., Gao, C., Liu, M., Peng, M., & Wang, L. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03620-1 · Cited by 3
Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?
Suda, K. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.05.21 · Cited by 2
Guo, P., Xu, T., Jiang, Y., & Shen, W. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-2676 · Cited by 3
Liu, M., Yu, X., Qu, C., & Xu, S. (2023) · Medicina · doi:10.3390/medicina59030547 · Cited by 3
Wen, B., Yu, H., Zhang, X., Wang, Y., & Ni, B. (2024) · IUBMB Life · doi:10.1002/iub.2813 · Cited by 3
Targeting the evolution of drug resistance in lung cancer
Shah, K. N., & Bandyopadhyay, S. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1603092 · Cited by 3
Self-citationGao, Z., Han, H., Zhao, Y., Yuan, H. S., Zheng, S., Zhang, Y., & Chen, H. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03718-z · Cited by 3
Hefni, D., ANANDA, Z., & Putra, P. P. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025.v17s1.08 · Cited by 2
Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy
Fu, L., & Luo, M. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_8 · Cited by 2
Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets
Zhang, K.-Y., Zhu, X.-Z., Yan, Y., Ying, X.-H., Zhang, J., & Wang, Z. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02850-x · Cited by 3
Mukherjee, A., Mukherjee, G., & Das, S. (2026) · Onco · doi:10.3390/onco6030036 · Cited by 2
A novel pyrrole-imidazole polyamide targets Aurora kinase A and suppresses tumor growth in vivo
Li, M., Lu, D., Cheng, Y., Wu, C., Zhang, J., Shi, W., Ding, Z., Li, Y., Cheng, B., Lin, X., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.07.077 · Cited by 2
Liu, T., & Wei, J. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02430-8 · Cited by 2
Sachdeva, A., Roy, A., & Mandal, S. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04986-2 · Cited by 2
Decoding oral cancer: insights from miRNA expression profiles and their regulatory targets
Wang, X., Zhang, S., Wang, S., Cao, T., & Fan, H. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1521839 · Cited by 2
Li, Y., Liu, P., Liu, S., Zhu, J., Han, Y., Jiang, Z., Tang, D., Meng, Z., Li, S., Zhang, M., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156788 · Cited by 2
Aurora kinases shed light on resistance to EGFR inhibition in head and neck cancer
Kim, D., & Bandyopadhyay, S. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103257 · Cited by 2
Self-citationWang, H., Zhang, J., Zhang, J., Hou, W., Zhou, J., Li, M., Liu, X., Li, Y., Fu, F., Tian, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.12.642829 · Cited by 2
Hou, Z., Wang, Z., Yang, F., Han, X., Li, L., & Liu, H. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70097 · Cited by 1
Wu, X. J., Yang, L., Li, Y., Zhu, A., Wang, T., Su, F., Wang, Z., Chen, Y., & Song, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-20159-7 · Cited by 1
Mi, Y., Mao, J., Li, X., Wang, Z., Zuo, X., Chang, Z., Wang, R., Wang, L., & Wang, L. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05427-4 · Cited by 1
Cytoskeletal remodeling via CAMSAP3 downregulation drives resistance to osimertinib in NSCLC cells
Yang, F., Wang, Z., Han, X., Zhong, J., Hou, Z., Bian, S., Long, J., & Liu, H. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08299-0 · Cited by 2
KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors
Uras, I. Z., Trkulja, M. V., Salama, A. K. A. A., Horvath, J., Asnani, K., Trenk, C., Kubicek, S., Bilban, M., Moll, H. P., & Casanova, E. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01242-8 · Cited by 1
Pinto, B. F., Silva, J. P. N., Silva, P. M. A., Sarmento, B. F. C. C., Carvalho‐Tavares, J., & Bousbaa, H. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040402 · Cited by 1
Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance
Zhao, Y., Zhou, Y., Pan, L., Tian, G. G., Huang, H., Tang, S., Lu, M., Zhou, Z., Zhang, P., Chen, L., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci191735 · Cited by 1
A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases
Nasief, N. N., Patel, K. B., Ogboo, B. C., & Heppner, D. E. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00330 · Cited by 1
Li, J., Li, Y., Jin, M. Y., Huang, L., & Wang, X. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2110 · Cited by 1
Computational identification and experimental characterization of an aurora kinase inhibitor
Muddassar, M., Furqan, M., Yousaf, N., Khalid, M. S., Mahmood, N., Dar, S., Fozail, S., Saleem, R. S. Z., Shahzad‐ul‐Hussan, S., & Faisal, A. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118160 · Cited by 1
Yang, X., Liu, Y., Jiang, W. H., Liu, X., Zhang, X., Liu, H., Xing, D., Wang, K., Zheng, X., & Jiang, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-16615-z · Cited by 1
Celeste, F., & Powers, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1598602/v1 · Cited by 1
In the literature: February 2019
Insa, A., Gambardella, V., & Cervantes, A. M. R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000490
[Research Progress of New Generation EGFR-TKIs after Third-generation].
Liu, Y., Yihui, L. I., & Wang, J. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.28
Zhu, X., Lu, Y., Chen, Q., & Li, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-396954/v1
Biomaterials modulation of the tumor immune environment for cancer immunotherapy
Wolf, M. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821440-4.00004-9
Nakaoka, H. J., Bennett, N. K., Okimoto, R. A., Laurent, D., Sei, Y. J., Bivona, T. G., ten Hoeve, J., Graeber, T. G., Nakamura, K., & Nakamura, J. L. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.03.462937
Self-citationImproving cancer therapy through unconventional strategies
Neto, J. M. F. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/1009
The Expression and Prognosis for Aurora kinases in Human non-small cell lung cancerPreprint
Ji, Z., Wang, Y., Zhang, C., Cao, X., Li, Y., & Guan, M. (2022) · Research Square · doi:10.21203/rs.3.rs-2278189/v1
Wang, R., Lin, X., Pan, F., Abudoureyimu, M., Wang, T., & Hao, L. (2022) · Research Square · doi:10.21203/rs.3.rs-2355508/v1
Scalabrini, L. C. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2022.tde-02122022-155942
Luo, M., Zhou, Y., Gu, W.-M., Wang, C., Shen, N.-X., Dong, J.-K., Lei, H.-M., Tang, Y., Liang, Q., Zou, J.-H., et al. (2023) · doi:10.1158/0008-5472.c.6513966.v1
Kashima, Y., Shibahara, D., Suzuki, A., Muto, K., Kobayashi, I. S., Plotnick, D. O., Udagawa, H., Izumi, H., Shibata, Y., Tanaka, K., et al. (2023) · doi:10.1158/0008-5472.c.6512902.v1
Luo, M., Zhou, Y., Gu, W.-M., Wang, C., Shen, N.-X., Dong, J.-K., Lei, H.-M., Tang, Y., Liang, Q., Zou, J.-H., et al. (2023) · doi:10.1158/0008-5472.c.6513966
Jiao, Y., Cheng, M., Li, H., Yang, H., & Li, X. (2023) · Indian Journal of Animal Research · doi:10.18805/ijar.bf-1617
Aurka inhibition-based combination therapy approaches in glioblastoma.
Sak, M. (2023) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/4149
Yeo, H., Lee, H., Park, S., & Kang, H. N. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4889165
Devrim, T., Devrim, A. K., Şenol, A., Sudağıdan, M., & Atalay, E. S. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-024-00004-5
Jiang, M., Bai, Y., Li, J., Wu, J., Hu, X., Ye, H., Bu, L., Gao, Z., Li, R., & Zheng, Y. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01555
Bertran-Alamillo, J., Giménez-Capitán, A., Roman, R. A., Talbot, S., Whiteley, R., Floc’h, N., Martínez‐Pérez, E., Martin, M. J., Smith, P. D., Sullivan, I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26603929
Additional file 2 of Predicting drug response from single-cell expression profiles of tumours
Pellecchia, S., Viscido, G., Franchini, M., & Gambardella, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648316
Additional file 1 of Predicting drug response from single-cell expression profiles of tumours
Pellecchia, S., Viscido, G., Franchini, M., & Gambardella, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648313
Lu, L., Cheng, H., Liu, S., Tao, Y., Fu, S., Lu, J., Gong, Y., Ding, H., Tian, J., Li, L., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0507
Targeted Therapy-Induced Chromosomal Instability Dictates Mitotic Dependency on Aurora Kinase APreprint
Li, C., Nangia, V., Vieira, M. D., Nimbalkar, A., Graser, C. J., Chang, J. B., Syed, M. U., Shen, Y., Koranne, R., Zou, L., et al. (2026) · SSRN Electronic Journal · doi:10.64898/2026.01.22.701085
Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma
Léonce, C. (2021) · theses.fr (ABES) · doi:10.70675/0611e924z7044z428cz90dcz9235e0a4b5a2
Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation
Kong, L., Zhong, F., Yu, F., Wang, T., Wang, G., Bai, Y. H., Xia, H., Pan, Z., Liu, M., Zhang, Y., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2516469123
Tian, C., Cui, L., & Wang, X. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04358-w
Jiang, M., Ye, H., Li, J., Wu, J., Hu, X., Long, Q., Bu, L., Gao, Z., & Zheng, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1724797
Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities
Li, M., Tang, S., Yang, P., & Zhou, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1713277
Zhu, J., Ren, S., Cheng, T., Shan, G., Lin, H., Huang, X., Bian, Y., Duan, L., Hu, Y., Wu, Y., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03792-6
Gini, B., Gui, P., Wu, W., Kerr, D. L., Tan, L., Barbosa, D., Olivas, V., Allegakoen, P., Gomez, C., Halliday, P. R., et al. (2026) · eLife · doi:10.7554/elife.111526.1
Self-citationGini, B., Gui, P., Wu, W., Kerr, D. L., Tan, L., Barbosa, D., Olivas, V., Allegakoen, P., Gomez, C., Halliday, P. R., et al. (2026) · eLife · doi:10.7554/elife.111526
Self-citationSilva, F. N., Lee, J. W., Nguyen, T. T., Goeckel, F. M., Bagnyukova, T., Borghaei, H., Golemis, E. A., & Burtness, B. A. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0368
Yang, Y., Liang, J., Wang, L., Zhang, H., Zhang, Z., Liu, Y., Zhu, R., Xu, W., Xu, S., Sun, D., et al. (2026) · Advanced Science · doi:10.1002/advs.78310
Metadata
- Authors
- Shah, K. N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Wang, V. E., Hemmati, G., Martins, M. M., Maynard, A., Kuhn, J., Galeas, J., Donnella, H. J., Kaushik, S., Ku, A., Dumont, S., Krings, G., Haringsma, H. J., Robillard, L., Simmons, A. D., Harding, T. C., McCormick, F., Goga, A., Blakely, C. M., Bivona, T. G., & Bandyopadhyay, S.
- Affiliations
- University of California, San Francisco (US)
- Clovis Oncology (United States) (US)
- Corresponding author
- Bandyopadhyay, Sourav
- ORCID
- Venue
- Nature Medicine
- Published
- 2018-11-26
- Volume
- 25
- Issue
- 1
- Pages
- 111-118
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6324945
- OpenAlex
- W2901591386
- Cited by
- 286
- References
- 43
- Citations by year
- 2026: 19 · 2025: 43 · 2024: 33 · 2023: 37 · 2022: 44 · 2021: 54 · 2020: 37 · 2019: 18 · 2018: 1
- FWCI
- 20.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Doris Duke Charitable Foundation (2018110)
- National Cancer Institute (R01CA169338, U01CA217882, U01CA168370, U54CA224081)
- National Institute of General Medical Sciences (R01GM107671)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- AURKA, TPX2, EGFR inhibitors, acquired drug resistance, EGFR-mutant lung adenocarcinoma, drug tolerance, residual disease, apoptosis, synthetic lethality, Aurora kinase inhibitors
- MeSH terms
- Animals, Cell Count, Humans, Lung Neoplasms, Microtubule-Associated Proteins, Mutation, Nuclear Proteins, Phosphorylation, Apoptosis, Neoplasm, Residual, Cell Cycle Proteins, Drug Resistance, Neoplasm, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Aurora Kinase A, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
